What are the best treatments for Hidradenitis Suppurativa?

TL;DR: Treatment for Hidradenitis Suppurativa (HS) is highly personalized, typically involving a combination of topical and systemic antibiotics, anti-inflammatory medications, and targeted biologic therapies to manage inflammation. While there is no definitive cure, surgical interventions—ranging from incision and drainage to wide local excision—are often necessary to manage recurring abscesses, scarring, and sinus tracts.

What are the current first-line treatments for Hidradenitis Suppurativa?

Management of Hidradenitis Suppurativa focuses on reducing inflammation, preventing secondary infections, and managing pain. For mild to moderate disease, dermatologists often prescribe topical clindamycin to reduce bacterial load and inflammation. If the condition is more extensive, systemic treatments are introduced. The only FDA-approved biologic for the treatment of moderate-to-severe Hidradenitis Suppurativa is adalimumab (Humira), which works by inhibiting TNF-alpha, a key protein involved in the inflammatory process. Other common systemic treatments include tetracycline-class antibiotics (such as doxycycline or minocycline) used for their anti-inflammatory properties rather than just their antibiotic effects.

What surgical and non-pharmacological options exist for Hidradenitis Suppurativa?

Because Hidradenitis Suppurativa often involves the formation of deep sinus tracts and extensive scarring, surgery is frequently required. Treatment plans often incorporate the following approaches:

• Incision and Drainage: Used for acute relief of painful, swollen abscesses, though it often results in recurrence.


• Deroofing: A surgical procedure where the top of the sinus tract is removed, allowing the wound to heal from the inside out; this is often more effective than simple drainage.


• Wide Local Excision: The surgical removal of the entire affected skin area, which is considered one of the most definitive treatments for chronic, recurrent lesions.


• Laser Therapy: CO2 laser treatment is increasingly used to vaporize diseased tissue and minimize the recurrence of Hidradenitis Suppurativa in affected areas.


• Lifestyle Modifications: Smoking cessation and weight management are strongly encouraged, as both have been clinically linked to disease severity.

What is the role of a multidisciplinary care team?

Managing Hidradenitis Suppurativa requires a team-based approach because the disease impacts multiple body systems, including the immune and endocrine systems. A comprehensive care team typically includes a dermatologist (the primary lead), a plastic or general surgeon for procedural interventions, and a pain management specialist. Given the significant psychological burden reported by the 729 members of our DiseaseMaps.org community, a clinical psychologist or counselor is also a vital member of the team to help manage the mental health impact of living with a chronic, stigmatized skin condition.

How do emerging treatments and clinical trials impact Hidradenitis Suppurativa?

Research into Hidradenitis Suppurativa is rapidly evolving. Recent clinical trials are investigating the efficacy of newer biologics that target different inflammatory pathways, such as IL-17 and IL-23 inhibitors. These emerging therapies aim to provide better outcomes for patients who do not respond to traditional treatments like adalimumab. Because Hidradenitis Suppurativa severity varies significantly between individuals, participation in clinical trials can offer patients access to cutting-edge therapies that are not yet widely available.

Next steps

• Consult a board-certified dermatologist who specializes in Hidradenitis Suppurativa to discuss a personalized treatment plan.


• Keep a symptom diary to track triggers, flares, and the effectiveness of current medications.


• Join the DiseaseMaps.org community to connect with others sharing their experiences with Hidradenitis Suppurativa.


• Inquire with your physician about ongoing clinical trials if standard therapies have failed to provide relief.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice; please consult with your healthcare provider for diagnosis and treatment of Hidradenitis Suppurativa.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Hidradenitis Suppurativa overview.


• Orphanet: Rare disease database entry for Hidradenitis Suppurativa (ORPHA:93375).


• American Academy of Dermatology (AAD): Clinical guidelines for the management of Hidradenitis Suppurativa.


• PubMed/NCBI: Current literature on biologic therapies and surgical outcomes for Hidradenitis Suppurativa.